Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis
American Journal of Cardiovascular Drugs · 2024
DOI: 10.1007/s40256-023-00616-2 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift American Journal of Cardiovascular Drugs, 2024. Verfasst von Mostafa Reda Mostafa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Rochester Regional Health/Unity Hospital, Rochester, NY, USA. Moustafazaalouk33@gmail.com. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Myocardial Infarction, Percutaneous Coronary Intervention, Thrombosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Cangrelor is a potent intravenous non-thienopyridine P2Y12 inhibitor. We conducted a network meta-analysis to study the efficacy and safety of cangrelor as compared with the oral P2Y12 inhibition, clopidogrel, or placebo in acute coronary syndromes. METHODS: This meta-analysis followed the Cochrane collaboration guidelines and the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) protocols. Outcomes of interest included all-cause mortality, myocardial infarction, stent thrombosis, target vessel revascularization, major bleeding, minor bleeding, and the need for blood transfusion. RESULTS: The analysis was comprised of 6 studies including 26,444 patients treated with cangrelor, clopidogrel, or placebo. There were no statistically significant differences in the incidence of all-cause mortality, myocardial infarction, stent thrombosis, target vessel revascularization, or major bleeding. Cangrelor was associated with a higher risk of minor bleeding than clopidogrel or placebo, with no difference in requiring blood transfusion. CONCLUSION: Cangrelor has comparable outcomes to clopidogrel in patients with acute coronary syndromes and can be used as a reliable alternative in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rochester Regional Health/Unity Hospital, Rochester, NY, USA. Moustafazaalouk33@gmail.com.
- Rochester Regional Health/Unity Hospital, Rochester, NY, USA.
- Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
- Department of Medicine, Rochester General Hospital, Rochester, NY, USA.
- Faculty of Medicine, Tanta University, Tanta, Egypt.
- Faculty of Medicine, Jordan University of Science and Technology, Amman, Jordan.
Zitieren
APA
Mostafa, M. R., Eid, M. M., Awad, A. K., Takla, A., Hassan, A. R., Katamesh, B. E., AlBarakat, M. M., Ziada, A. R., Mohamed, S., Al-Azizi, K. M., & Goldsweig, A. M. (2024). Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-023-00616-2
Vancouver
Mostafa MR, Eid MM, Awad AK, Takla A, Hassan AR, Katamesh BE, et al. Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis. American Journal of Cardiovascular Drugs. 2024. doi:10.1007/s40256-023-00616-2
BibTeX
@article{Mostafa2024,
author = {Mostafa, Mostafa Reda and Eid, Mohamed Magdi and Awad, Ahmed K and Takla, Andrew and Hassan, Abdul Rhman and Katamesh, Basant E and AlBarakat, Majd M and Ziada, Abdul Rhman and Mohamed, Sarah and Al-Azizi, Karim M and Goldsweig, Andrew M},
title = {Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis},
journal = {American Journal of Cardiovascular Drugs},
year = {2024},
doi = {10.1007/s40256-023-00616-2}
}
EUVIMED